ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Dual-Mode Type I/II Photosensitization of a Stable Mesoporous Hydrogen-Bonded Organic Framework for Antibacterial Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In contrast to monomers that are randomly distributed in solution or in an amorphous state, constructing a highly crystalline framework with precise molecular arrangement might provide materials with markedly enhanced functionalities. Herein, a large π-conjugated electron donor-acceptor (D-A) type molecule was designed and synthesized, which self-assembles through hydrogen bonds to form an organic framework named PFC-513. The ordered arrangement dramatically boosts the quantum yield (ΦΔ) of singlet oxygen generation, classified as type IIreactive oxygen species (ROS), from 0.01 for the monomer to 0.98 for PFC-513, while enabling the hydroxyl radical generation (type I ROS), which is absent in the monomeric state. Such dual-mode Type I/II Photosensitization grants PFC-513 potent antibacterial activity against methicillin-resistant bacteria and E. coli. Beyond direct antibacterial action, PFC-513 can simultaneously downregulate key pro-inflammatory cytokines and chemokines under light irradiation for a diabetic wound, therefore synergistically accelerating wound healing. This work establishes a new paradigm for engineering crystalline porous frameworks with superior PDT efficacy, offering a promising strategy for combating infections and promoting wound repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.